Background: The pandemic of Coronavirus Disease 2019 (COVID-19) has been a threat to global health. In the US, the Centers for Disease Control and Prevention (CDC) has listed 12 comorbidities within the first tier that increase with the risk of severe illness from COVID-19, including the comorbidities that are common with increasing age (referred to as age-related comorbidities) and other comorbidities. However, the current method compares a population with and without a particular disease (or disorder), which may result in a bias in the results. Thus, comorbidity risks of COVID-19 mortality may be underestimated. Objective: To re-evaluate the mortality data from the US and estimate the odds ratios of death by major comorbidities with COVID-19, we incorporated the control population with no comorbidity reported and assessed the risk of COVID-19 mortality with a comorbidity. Methods: We collected all the comorbidity data from the public health websites of fifty US States and Washington DC (originally accessed on December 2020). The timing of the data collection should minimize bias from the COVID-19 vaccines and new COVID-19 variants. The comorbidity demographic data were extracted from the state public health data made available online. Using the inverse variance random-effects model, we performed a comparative analysis and estimated the odds ratio of deaths by COVID-19 with pre-existing comorbidities. Results: A total of 39,451 COVID-19 deaths were identified from four States that had comorbidity data, including Alabama, Louisiana, Mississippi, and New York. 92.8% of the COVID-19 deaths were associated with a pre-existing comorbidity. The risk of mortality associated with at least one comorbidity combined was 1113 times higher than that with no comorbidity. The comparative analysis identified nine comorbidities with odds ratios of up to 35 times higher than no comorbidities. Of them, the top four comorbidities were: hypertension (odds ratio 34.73; 95% CI 3.63–331.91; p = 0.002), diabetes (odds ratio 20.16; 95% CI 5.55–73.18; p < 0.00001), cardiovascular disease (odds ratio 18.91; 95% CI 2.88–124.38; p = 0.002), and chronic kidney disease (odds ratio 12.34; 95% CI 9.90–15.39; p < 0.00001). Interestingly, lung disease added only a modest increase in risk (odds ratio 6.69; 95% CI 1.06–42.26; p < 0.00001). Conclusion: The aforementioned comorbidities show surprisingly high risks of COVID-19 mortality when compared to the population with no comorbidity. Major comorbidities were enriched with pre-existing comorbidities that are common with increasing age (cardiovascular disease, diabetes, and hypertension). The COVID-19 deaths were mostly associated with at least one comorbidity, which may be a source of the bias leading to the underestimation of the mortality risks previously reported. We note that the method has limitations stemming primarily from the availability of the data. Taken together, this type of study is useful to approximate the risks, which most likely provide an updated awareness of age-related comorbidities.
Human genomic analysis and genome-wide association studies (GWAS) have identified genes that are risk factors for early and late-onset Alzheimer’s disease (AD genes). Although the genetics of aging and longevity have been extensively studied, previous studies have focused on a specific set of genes that have been shown to contribute to or are a risk factor for AD. Thus, the connections among the genes involved in AD, aging, and longevity are not well understood. Here, we identified the genetic interaction networks (referred to as pathways) of aging and longevity within the context of AD by using a gene set enrichment analysis by Reactome that cross-references more than 100 bioinformatic databases to allow interpretation of the biological functions of gene sets through a wide variety of gene networks. We validated the pathways with a threshold of p-value < 1.00 × 10−5 using the databases to extract lists of 356 AD genes, 307 aging-related (AR) genes, and 357 longevity genes. There was a broad range of biological pathways involved in AR and longevity genes shared with AD genes. AR genes identified 261 pathways within the threshold of p < 1.00 × 10−5, of which 26 pathways (10% of AR gene pathways) were further identified by overlapping genes among AD and AR genes. The overlapped pathways included gene expression (p = 4.05 × 10−11) including ApoE, SOD2, TP53, and TGFB1 (p = 2.84 × 10−10); protein metabolism and SUMOylation, including E3 ligases and target proteins (p = 1.08 × 10−7); ERBB4 signal transduction (p = 2.69 × 10−6); the immune system, including IL-3 and IL-13 (p = 3.83 × 10−6); programmed cell death (p = 4.36 × 10−6); and platelet degranulation (p = 8.16 × 10−6), among others. Longevity genes identified 49 pathways within the threshold, of which 12 pathways (24% of longevity gene pathways) were further identified by overlapping genes among AD and longevity genes. They include the immune system, including IL-3 and IL-13 (p = 7.64 × 10−8), plasma lipoprotein assembly, remodeling and clearance (p < 4.02 × 10−6), and the metabolism of fat-soluble vitamins (p = 1.96 × 10−5). Thus, this study provides shared genetic hallmarks of aging, longevity, and AD backed up by statistical significance. We discuss the significant genes involved in these pathways, including TP53, FOXO, SUMOylation, IL4, IL6, APOE, and CEPT, and suggest that mapping the gene network pathways provide a useful basis for further medical research on AD and healthy aging.
Background: The pandemic of Coronavirus Disease 2019 (COVID-19) has been a threat to global health in the world. In the US, the Centers for Disease Control and Prevention (CDC) has listed 12 comorbidities within the first tier that increase with the risk of severe illness from COVID-19, including the comorbidities that are common with increasing age (referred to as age-related comorbidities) and other comorbidities. However, the current method compares a population with and without a particular disease (or disorder), which may result in a bias on the results. Thus, comorbidity risks of COVID-19 mortality may be underestimated. Objective: To re-evaluate the mortality data from US States and estimate the odds ratios of death by major comorbidities with COVID-19, we incorporated the control population with no comorbidity reported and assessed the risk of COVID-19 mortality with comorbidity. Methods: We collected all the comorbidity data from the Public Health websites of fifty US States and Washington DC accessed on December 2020. The timing of the data collection should allow minimizing a bias from the COVID-19 vaccines and new COVID-19 variants. The comorbidity demographic data were extracted from the State Public Health data made available online. Using the inverse-variance random-effects model, we performed a comparative analysis and estimated the odds ratio of deaths by COVID-19 with pre-existing comorbidities. Results: A total of 39,451 COVID-19 deaths were identified from four States that had comorbidity data, including Alabama, Louisiana, Mississippi, New York. 92.8% of the COVID-19 deaths were associated with pre-existing comorbidity. The risk of mortality associated with at least one comorbidity combined was 1,113 times higher than that with no comorbidity. The comparative analysis identified nine comorbidities with odds ratios of up to 35 times significantly higher than no comorbidities. Of them, the top four comorbidities were: hypertension (odds ratio 34.73; 95% CI 3.63-331.91; p = 0.002), diabetes (odds ratio 20.16; 95% CI 5.55-73.18; p < 0.00001), cardiovascular disease (odds ratio 18.91; 95% CI 2.88-124.38; p = 0.002); and chronic kidney disease (odds ratio 12.34; 95% CI 9.90-15.39; p < 0.00001). Interestingly, lung disease added only a modest increase in risk (odds ratio 6.69; 95% CI 1.06-42.26; p < 0.00001). Conclusion: The aforementioned comorbidities show surprisingly high risks of COVID-19 mortality when compared to the population with no comorbidity. Major comorbidities were enriched with pre-existing comorbidities that are common with increasing age (cardiovascular disease, diabetes, and hypertension). The COVID-19 deaths were mostly associated with at least one comorbidity, which may be a source of the bias leading to the underestimation of the mortality risks previously reported. Taken together, this type of study is useful to approximate the risks, which most likely provide an updated awareness of age-related comorbidities.
Human genomic analysis and genome-wide association studies (GWAS) have identified genes that are risk factors for early and late-onset Alzheimer's disease (AD genes). Although the genetics of aging and longevity has been extensively studied, previous studies have focused on a specific set of genes that have been shown to contribute to or to be a risk factor for AD. Thus, the connections among the genes involved in AD, aging, and longevity are not well understood. Here, we identified the genetic interaction networks (referred to as pathways) of aging and longevity within the context of AD, using a gene set enrichment analysis by Reactome that cross-references more than 100 bioinformatic databases to allow interpretation of the biological functions of gene sets through a wide variety of gene networks. We validated the pathways with a threshold of p-value < 1.00E-05, using the databases to extract lists of 356 AD genes, 307 aging-related (AR) genes, and 357 longevity genes. There was a broad range of biological pathways involved in AR and Longevity genes shared with AD genes. AR genes identified 261 pathways within the threshold of p < 1.00E-05, of which 26 pathways (10% of AR gene pathways) were further identified by overlapping genes among AD and AR genes. The overlapped pathways included Gene Expression (p = 4.05E-11) including ApoE, SOD2, TP53 and TGFB1 (p = 2.84E-10); Protein Metabolism and SUMOylation including E3 ligases and target proteins (p = 1.08E-07), ERBB4 signal transduction (p = 2.69E-06), Immune System including IL-3 and IL-13 (p = 3.83E-06), Programmed Cell Death (p = 4.36E-06) and platelet degranulation (p = 8.16E-06) among others. Longevity genes identified 49 pathways within the threshold, of which 12 pathways (24% of Longevity gene pathways) were further identified by overlapping genes among AD and Longevity genes. They include the immune system including IL-3 and IL-13 (p = 7.64E-08), plasma lipoprotein assembly, remodeling and clearance (p < 4.02E-06), metabolism of fat-soluble vitamins (p = 1.96E-05). Thus, this study provides shared genetic hallmarks of aging, longevity, and AD backed up by statistical significance. We discuss significant genes involved in these pathways, including TP53, FOXO, Sumoylation, IL4, IL6, APOE, and CEPT, and suggest that mapping the gene network pathways provide a useful basis for further medical research, education, and community outreach.
Ammonia lyases and aminomutases are emerging as important enzymatic systems, not only in green synthetic routes to chiral amines, but also as potential target for enzyme therapeutic for treating diseases such as phenylketonuria and cancer (1). On the other hand, b-amino acids harbor many applications in their free form and as building blocks of bioactive compounds (2, 3). Although, these eco-friendly biocatalytic routes have been extensively explored, they are far from optimal. The aim of this work is to engineer a phenylalanine aminomutase (PAM) to acquire lyase properties for the efficient production of enantio-pure b-Phe (key component of taxol ( 2)). Thus, this study was guided by molecular modeling techniques to decipher which structural components functionally separate PAM and the phenylalanine ammonia lyase (PAL). Despite the great structural similarity of the active site of these enzymes, PAL is a-selective with much faster deamination rates relative to PAM, which exhibits 50% aand bregioselectivity (1, 4). Recent studies have implicated loop regions as key structural determinants between PAM and PAL (5). Here, we report novel insight into the implications of the active-site loop residues of PAM, which influence mutase/lyase activity. Several mutants were proposed, cloned, expressed and characterized. Overall, this enzyme engineering work represents the first successful attempt to convert a PAM to a PAL through strict mutase-to-lyase residue mutations. Such a breakthrough may guide future investigations into the functional determinants of these enzymes and possibly foster the engineering of faster PAM variants used for the efficient synthesis of b-Phe.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.